UA117455C2 - Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора - Google Patents

Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора

Info

Publication number
UA117455C2
UA117455C2 UAA201411324A UAA201411324A UA117455C2 UA 117455 C2 UA117455 C2 UA 117455C2 UA A201411324 A UAA201411324 A UA A201411324A UA A201411324 A UAA201411324 A UA A201411324A UA 117455 C2 UA117455 C2 UA 117455C2
Authority
UA
Ukraine
Prior art keywords
treatment
lung cancer
auror
application
kinas
Prior art date
Application number
UAA201411324A
Other languages
English (en)
Ukrainian (uk)
Inventor
Аріджіт Чхакраварті
Джеффрі А. Екседі
Роберт В. Клєйнфілд
Кха Н. Ле
Вен Чйі Схю
Картхік Венкатакрішнан
Original Assignee
Мілленіум Фармасьютікалз, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мілленіум Фармасьютікалз, Інк. filed Critical Мілленіум Фармасьютікалз, Інк.
Publication of UA117455C2 publication Critical patent/UA117455C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201411324A 2012-03-20 2013-03-19 Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора UA117455C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
UA117455C2 true UA117455C2 (uk) 2018-08-10

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201411324A UA117455C2 (uk) 2012-03-20 2013-03-19 Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора

Country Status (24)

Country Link
US (2) US20130303519A1 (https=)
EP (1) EP2827855B1 (https=)
JP (1) JP6373252B2 (https=)
KR (1) KR102128866B1 (https=)
CN (1) CN104271129A (https=)
AU (1) AU2013235275B2 (https=)
CA (1) CA2868024A1 (https=)
EA (1) EA036434B1 (https=)
ES (1) ES2746946T3 (https=)
GE (2) GEAP201813599A (https=)
IL (1) IL234686B (https=)
IN (1) IN2014DN08477A (https=)
JO (1) JO3630B1 (https=)
MA (1) MA37438A1 (https=)
MX (1) MX358411B (https=)
MY (1) MY175225A (https=)
NZ (1) NZ700744A (https=)
PH (1) PH12014502109A1 (https=)
SG (2) SG10201607741RA (https=)
TN (1) TN2014000387A1 (https=)
TW (1) TWI649082B (https=)
UA (1) UA117455C2 (https=)
WO (1) WO2013142491A1 (https=)
ZA (1) ZA201407551B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
WO2016106357A1 (en) * 2014-12-23 2016-06-30 Millennnium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
JP6786530B2 (ja) * 2015-07-02 2020-11-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラａキナーゼの選択的インヒビターに対する応答のバイオマーカー
CN110833544B (zh) * 2018-08-17 2022-08-09 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
CA1138863A (en) 1979-02-07 1983-01-04 Norman W. Gilman Benzazepine-derivatives
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
KR19990087585A (ko) 1996-03-08 1999-12-27 돈 리사 로얄 신경학적 활성제로서의 아졸로벤즈아제핀 유도체
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
DK1026167T3 (da) 1997-09-29 2003-05-26 Meiji Seika Kaisha Tricykliske triazolobenzazepinderivater, fremgangsmåde til fremstilling af disse samt antiallergiske midler
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
NZ526472A (en) 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
JP4364637B2 (ja) 2001-08-09 2009-11-18 アクテリオン ファーマシューティカルズ リミテッド 新規なベンゾ縮合へテロ環化合物
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
EP1718303A4 (en) 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
ES2540987T3 (es) 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
SI1962830T1 (sl) 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
JP2009523784A (ja) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
WO2008020314A2 (en) 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
EP2077850A2 (en) 2006-10-31 2009-07-15 Achillion Pharmaceuticals, Inc. Elvucitabine pharmaceutical compositions
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
MX379265B (es) 2008-06-26 2025-03-11 Anterios Inc Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CA2788774A1 (en) * 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Also Published As

Publication number Publication date
MX358411B (es) 2018-08-20
IN2014DN08477A (https=) 2015-05-08
TN2014000387A1 (en) 2015-12-21
TW201343169A (zh) 2013-11-01
US20130303519A1 (en) 2013-11-14
HK1206253A1 (en) 2016-01-08
KR102128866B1 (ko) 2020-07-01
TWI649082B (zh) 2019-02-01
NZ700744A (en) 2016-09-30
CA2868024A1 (en) 2013-09-26
AU2013235275A1 (en) 2014-10-23
EA036434B1 (ru) 2020-11-10
WO2013142491A1 (en) 2013-09-26
EP2827855B1 (en) 2019-06-26
IL234686B (en) 2020-01-30
AU2013235275B2 (en) 2017-12-07
EP2827855A1 (en) 2015-01-28
EA201491727A1 (ru) 2015-01-30
GEAP201813599A (en) 2018-06-25
KR20140144215A (ko) 2014-12-18
CN104271129A (zh) 2015-01-07
ZA201407551B (en) 2019-01-30
MY175225A (en) 2020-06-16
PH12014502109A1 (en) 2014-12-10
US10213436B2 (en) 2019-02-26
MA37438A1 (fr) 2016-05-31
IL234686A0 (en) 2014-11-30
GEP20186900B (en) 2018-10-10
JP2015510945A (ja) 2015-04-13
JO3630B1 (ar) 2020-08-27
US20160193224A1 (en) 2016-07-07
ES2746946T3 (es) 2020-03-09
JP6373252B2 (ja) 2018-08-15
SG11201405621UA (en) 2014-10-30
MX2014011324A (es) 2014-12-05
SG10201607741RA (en) 2016-11-29

Similar Documents

Publication Publication Date Title
IL289300A (en) Combination therapy for treating cancer
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
EA201400178A1 (ru) Лечение рака молочной железы
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
SI3725810T1 (sl) Kombinacijska terapija, ki vključuje protitelesa proti klavdinu 18.2 za zdravljenje raka
EA201590987A1 (ru) Соединения и способы их применения
DK2922828T3 (da) 4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer
PT2897620T (pt) Método de tratamento de cancro
EA201590997A1 (ru) Соединения и способы их применения
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
BR112014009755A2 (pt) tratamento de câncer com inibidores de quinase tor
EA201490944A1 (ru) Двойной ингибитор met и vegf для лечения рака
EP2968254A4 (en) Methods of treating lung cancer
BR112013024211A2 (pt) tratamento de tumores sólidos
LT3371165T (lt) Btk inhibitorius, naudojamas vėžiui gydyti
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
KR102082363B9 (ko) 난소암의 치료를 위한 조합 치료
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
EP3252171B8 (en) Methods of treating cancer
EA201590656A1 (ru) Азаиндолины
EA201591709A1 (ru) 5-бром-индирубины
PL2928454T3 (pl) Triazyny do leczenia chorób wywoływanych przez pierwotniaki
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
UA117455C2 (uk) Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора